RejuvenRx

RejuvenRx is a Montreal-based private biotechnology company developing disease-modifying therapies for aging and cancer. The company focuses on stem cell biology, cellular aging/senescence, and oncology target discovery, and is advancing a pipeline centered on small molecules and molecular glue degraders. Its disclosed programs include an aging-focused pyrimidoindole series and oncology programs such as an RCOR1 degrader and a Cyclin K degrader, all at the preclinical stage. RejuvenRx positions its approach around a platform that combines oncology target identification, access to diversified small-molecule libraries, and internal drug optimization capabilities. The company appears to be an early-stage spinout connected to the Montreal ecosystem around IRIC, IRICoR, and ExCellThera.